Kenichi Harano

1.4k total citations
70 papers, 702 citations indexed

About

Kenichi Harano is a scholar working on Oncology, Obstetrics and Gynecology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kenichi Harano has authored 70 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 17 papers in Obstetrics and Gynecology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kenichi Harano's work include Endometrial and Cervical Cancer Treatments (17 papers), Ovarian cancer diagnosis and treatment (12 papers) and HER2/EGFR in Cancer Research (10 papers). Kenichi Harano is often cited by papers focused on Endometrial and Cervical Cancer Treatments (17 papers), Ovarian cancer diagnosis and treatment (12 papers) and HER2/EGFR in Cancer Research (10 papers). Kenichi Harano collaborates with scholars based in Japan, United States and Italy. Kenichi Harano's co-authors include Mayu Yunokawa, Kan Yonemori, Noriyuki Katsumata, Naoto T. Ueno, Masashi Ando, Yasuhiro Fujiwara, Kenji Tamura, Chikako Shimizu, Takayuki Kinoshita and Yuko Tanabe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kenichi Harano

60 papers receiving 689 citations

Peers

Kenichi Harano
Koji Kumagai Japan
Susan B. Ingersoll United States
Volker Moebus Germany
Christine Gennigens Belgium
Saverio Danese Italy
Martin Heubner Germany
Antonio Febbraro Italy
Alejandro Rojo‐Sebastián Spain
Svend A. Engelholm Denmark
Koji Kumagai Japan
Kenichi Harano
Citations per year, relative to Kenichi Harano Kenichi Harano (= 1×) peers Koji Kumagai

Countries citing papers authored by Kenichi Harano

Since Specialization
Citations

This map shows the geographic impact of Kenichi Harano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenichi Harano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenichi Harano more than expected).

Fields of papers citing papers by Kenichi Harano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenichi Harano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenichi Harano. The network helps show where Kenichi Harano may publish in the future.

Co-authorship network of co-authors of Kenichi Harano

This figure shows the co-authorship network connecting the top 25 collaborators of Kenichi Harano. A scholar is included among the top collaborators of Kenichi Harano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenichi Harano. Kenichi Harano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morisada, Tohru, Yoichi Kobayashi, Satoru Nagase, et al.. (2025). Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm. Journal of Gynecologic Oncology. 36(3). e119–e119. 1 indexed citations
2.
3.
Harano, Kenichi, et al.. (2024). Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance. Gynecologic Oncology Reports. 55. 101482–101482.
4.
Kuboki, Yasutoshi, Takafumi Koyama, Nobuaki Matsubara, et al.. (2024). PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer Medicine. 13(8). e6980–e6980. 9 indexed citations
5.
Doi, Toshihiko, Shunji Takahashi, Daisuke Aoki, et al.. (2024). A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 93(6). 605–616. 1 indexed citations
6.
Hirota, Akira, Nobuyuki Takahashi, Hiromichi Nakajima, et al.. (2023). The impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer. Cancer Medicine. 12(11). 12095–12105. 3 indexed citations
7.
Kuboki, Yasutoshi, Toshio Shimizu, Kan Yonemori, et al.. (2022). Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer Research Communications. 2(11). 1426–1435. 7 indexed citations
8.
Nishio, Shin, Kan Yonemori, Tomoka Usami, et al.. (2022). Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826. Cancer Science. 113(11). 3877–3887. 23 indexed citations
9.
Naito, Yoichi, Hiromichi Nakajima, Chihiro Kondoh, et al.. (2022). Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study. Japanese Journal of Clinical Oncology. 53(2). 105–114. 2 indexed citations
10.
Nakajima, Hiromichi, Kenichi Harano, Tokiko Nakai, et al.. (2022). Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. The Breast. 61. 136–144. 11 indexed citations
11.
Kawazoe, Akihito, Kota Itahashi, Noboru Yamamoto, et al.. (2021). TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research. 27(24). 6709–6715. 41 indexed citations
12.
Naito, Yoichi, Yasutoshi Kuboki, Masafumi Ikeda, et al.. (2021). Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. Investigational New Drugs. 39(6). 1568–1576. 9 indexed citations
13.
Mukohara, Toru, Ako Hosono, Sachiyo Mimaki, et al.. (2021). Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation. The Oncologist. 26(8). 635–639. 12 indexed citations
14.
Naito, Yoichi, Chihiro Kondoh, Kenichi Harano, et al.. (2021). The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. The Breast. 58. 50–56. 6 indexed citations
15.
Doi, Toshihiko, Yoichi Naito, Yasutoshi Kuboki, et al.. (2021). 545P First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part. Annals of Oncology. 32. S608–S609. 1 indexed citations
16.
17.
Kuboki, Yasutoshi, Nobuaki Matsubara, Hideaki Bando, et al.. (2017). First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. Annals of Oncology. 28. v124–v124. 9 indexed citations
18.
Harano, Kenichi, Xiudong Lei, Ana M. González-Angulo, et al.. (2016). Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 159(2). 367–374. 23 indexed citations
19.
20.
Harano, T., et al.. (1988). An Electrophoretically Silent Hewlobin Variant, HB Hekinan [α27(B8)GLU→ASP] Found in a Japanese. Hemoglobin. 12(1). 61–65. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koji Kumagai Breakdown of academic impact, for papers by Susan B. Ingersoll Breakdown of academic impact, for papers by Volker Moebus Breakdown of academic impact, for papers by Christine Gennigens Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by Martin Heubner Breakdown of academic impact, for papers by Antonio Febbraro Breakdown of academic impact, for papers by Alejandro Rojo‐Sebastián Breakdown of academic impact, for papers by Svend A. Engelholm
Rankless by CCL
2026